Revvity (RVTY)
Market Price (4/25/2026): $86.765 | Market Cap: $9.8 BilSector: Health Care | Industry: Health Care Equipment
Revvity (RVTY)
Market Price (4/25/2026): $86.765Market Cap: $9.8 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% Attractive yieldFCF Yield is 5.2% Stock buyback supportStock Buyback 3Y Total is 1.6 Bil Low stock price volatilityVol 12M is 38% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -108% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.02 | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 27x, P/EPrice/Earnings or Price/(Net Income) is 41x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.4% Key risksRVTY key risks include [1] intense pressure from larger, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Attractive yieldFCF Yield is 5.2% |
| Stock buyback supportStock Buyback 3Y Total is 1.6 Bil |
| Low stock price volatilityVol 12M is 38% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -108% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.02 |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 27x, P/EPrice/Earnings or Price/(Net Income) is 41x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.4% |
| Key risksRVTY key risks include [1] intense pressure from larger, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Lower-than-expected organic revenue growth outlook for 2026. Despite reporting adjusted EPS of $1.70 and revenue of $772.06 million for Q4 2025, which surpassed analyst estimates, Revvity's initiated full-year 2026 guidance for organic revenue growth of 2-3% appears to have disappointed investors. The Life Sciences segment's organic revenue growth was notably flat in Q4 2025. This modest growth projection, especially after a period of portfolio transformation, is perceived as a "low-single-digit organic growth outlook" contributing to investor de-risking.
2. Recent analyst downgrades and cautious price target adjustments. Several prominent analyst firms have lowered their price targets and adopted a more cautious stance on Revvity. For instance, Goldman Sachs issued a $95 price target on April 14, 2026, while Barclays and J.P. Morgan also set targets around $95-$96 in April 2026. This "recent wave of analyst caution" and a "Hold" consensus rating with an average score of 2.21 from analysts have weighed on the stock's performance.
Show more
Stock Movement Drivers
Fundamental Drivers
The -10.2% change in RVTY stock from 12/31/2025 to 4/24/2026 was primarily driven by a -13.3% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 96.62 | 86.77 | -10.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,813 | 2,856 | 1.5% |
| Net Income Margin (%) | 8.4% | 8.4% | 0.0% |
| P/E Multiple | 47.0 | 40.7 | -13.3% |
| Shares Outstanding (Mil) | 115 | 113 | 2.0% |
| Cumulative Contribution | -10.2% |
Market Drivers
12/31/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| RVTY | -10.2% | |
| Market (SPY) | 4.2% | 54.7% |
| Sector (XLV) | -6.9% | 41.4% |
Fundamental Drivers
The -0.8% change in RVTY stock from 9/30/2025 to 4/24/2026 was primarily driven by a -17.1% change in the company's Net Income Margin (%).| (LTM values as of) | 9302025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 87.46 | 86.77 | -0.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,798 | 2,856 | 2.1% |
| Net Income Margin (%) | 10.2% | 8.4% | -17.1% |
| P/E Multiple | 36.0 | 40.7 | 12.9% |
| Shares Outstanding (Mil) | 118 | 113 | 3.9% |
| Cumulative Contribution | -0.8% |
Market Drivers
9/30/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| RVTY | -0.8% | |
| Market (SPY) | 7.0% | 53.1% |
| Sector (XLV) | 4.0% | 48.2% |
Fundamental Drivers
The -17.7% change in RVTY stock from 3/31/2025 to 4/24/2026 was primarily driven by a -14.1% change in the company's P/E Multiple.| (LTM values as of) | 3312025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 105.42 | 86.77 | -17.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,755 | 2,856 | 3.7% |
| Net Income Margin (%) | 9.8% | 8.4% | -13.9% |
| P/E Multiple | 47.3 | 40.7 | -14.1% |
| Shares Outstanding (Mil) | 121 | 113 | 7.4% |
| Cumulative Contribution | -17.7% |
Market Drivers
3/31/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| RVTY | -17.7% | |
| Market (SPY) | 28.1% | 60.0% |
| Sector (XLV) | 0.1% | 62.2% |
Fundamental Drivers
The -34.3% change in RVTY stock from 3/31/2023 to 4/24/2026 was primarily driven by a -50.9% change in the company's Net Income Margin (%).| (LTM values as of) | 3312023 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 132.13 | 86.77 | -34.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,312 | 2,856 | -13.8% |
| Net Income Margin (%) | 17.2% | 8.4% | -50.9% |
| P/E Multiple | 29.3 | 40.7 | 38.9% |
| Shares Outstanding (Mil) | 126 | 113 | 11.6% |
| Cumulative Contribution | -34.3% |
Market Drivers
3/31/2023 to 4/24/2026| Return | Correlation | |
|---|---|---|
| RVTY | -34.3% | |
| Market (SPY) | 79.8% | 46.4% |
| Sector (XLV) | 16.6% | 52.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RVTY Return | 40% | -30% | -22% | 2% | -13% | -10% | -38% |
| Peers Return | 32% | -27% | -13% | -1% | 1% | -14% | -27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 89% |
Monthly Win Rates [3] | |||||||
| RVTY Win Rate | 83% | 50% | 42% | 33% | 42% | 25% | |
| Peers Win Rate | 73% | 37% | 48% | 47% | 50% | 25% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| RVTY Max Drawdown | -16% | -42% | -41% | -9% | -26% | -13% | |
| Peers Max Drawdown | -5% | -38% | -33% | -13% | -31% | -18% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, A, BIO, ILMN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/24/2026 (YTD)
How Low Can It Go
| Event | RVTY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -59.2% | -25.4% |
| % Gain to Breakeven | 145.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -34.4% | -33.9% |
| % Gain to Breakeven | 52.5% | 51.3% |
| Time to Breakeven | 77 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.1% | -19.8% |
| % Gain to Breakeven | 35.3% | 24.7% |
| Time to Breakeven | 87 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -63.0% | -56.8% |
| % Gain to Breakeven | 169.9% | 131.3% |
| Time to Breakeven | 1,285 days | 1,480 days |
Compare to TMO, DHR, A, BIO, ILMN
In The Past
Revvity's stock fell -59.2% during the 2022 Inflation Shock from a high on 12/31/2021. A -59.2% loss requires a 145.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Revvity (RVTY)
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Revvity (RVTY):
- It's like the Thermo Fisher Scientific for scientific research and diagnostic tools.
- Think of it as the Danaher of high-tech instruments and services for labs, healthcare, and environmental analysis.
AI Analysis | Feedback
```html- Life Sciences Research Technologies: Revvity provides instruments, reagents, informatics, software, detection, and imaging technologies to enhance research breakthroughs in life sciences.
- Contract Research and Laboratory Services: The company offers specialized contract research and laboratory services primarily for the life sciences research market.
- Environmental and Food Analysis Solutions: Revvity supplies analytical technologies, solutions, and services for assessing the health of air, water, and soil, as well as solutions for farmers and food producers.
- Industrial Analytical Instrumentation: The company offers analytical instrumentation and solutions for various industrial markets, including chemical, semiconductor, energy, and petrochemical industries.
- Diagnostic Products and Platforms: Revvity provides instruments, reagents, assay platforms, and software for the early detection of genetic disorders and infectious diseases.
- Genomic Workflow Technologies: The company develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery.
AI Analysis | Feedback
Revvity (RVTY) primarily sells its products, services, and solutions to other companies and organizations, rather than directly to individuals. Its major customers fall into the following categories:
- Pharmaceutical and biotechnology companies
- Laboratories (including contract research and analytical laboratories)
- Academic and research institutions
- Public health authorities
- Private healthcare organizations
- Doctors and healthcare providers
- Government agencies (including those in environmental, industrial, and public health sectors)
AI Analysis | Feedback
nullAI Analysis | Feedback
Prahlad Singh, PhD - President and Chief Executive Officer
Prahlad Singh was appointed President and Chief Executive Officer of Revvity (formerly PerkinElmer, Inc.) in 2019. He led the company through a significant transformation, including overseeing the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, which led to the creation of Revvity. Prior to joining PerkinElmer in 2014, Dr. Singh served as General Manager of GE Healthcare's Women's Health business. He also held senior executive roles in strategy, business development, and mergers and acquisitions at both GE Healthcare and Philips Healthcare. Dr. Singh holds a PhD in chemistry and an MBA.
Max Krakowiak - Senior Vice President and Chief Financial Officer
Max Krakowiak is the Senior Vice President and Chief Financial Officer at Revvity, a role he was appointed to in August 2022. He has been an integral part of Revvity's finance leadership team since 2018. Before becoming CFO, Mr. Krakowiak served as VP of Corporate Finance, overseeing financial planning and analysis, as well as the commercial and business development finance organizations. He also acted as the company's chief of staff for finance, focusing on global finance transformation. Prior to Revvity, Mr. Krakowiak spent seven years at GE, most recently as a member of the executive leadership team in their corporate audit staff, where he worked on corporate strategy, external investigations, and investor relations across GE's global operating segments. He is a graduate of the GE Financial Management leadership program and holds a bachelor's degree in finance from Fordham University. Notably, he was also a minor league baseball player for the Seattle Mariners organization.
Joel Goldberg - Senior Vice President, Administration, General Counsel and Secretary
Joel Goldberg serves as Senior Vice President, Administration, General Counsel and Secretary for Revvity. In this role, he provides expert insights and strategic thinking on a variety of legal, regulatory, and policy issues affecting the company. He leads dedicated and solutions-driven teams that collaborate across the business to offer support and guidance on various corporate matters.
Miriame Victor - Senior Vice President and Chief Commercial Officer
Miriame Victor is the Senior Vice President and Chief Commercial Officer at Revvity. She is responsible for leading a global team dedicated to bringing innovative products and solutions to market that address customer needs and expand human potential in health and science. Ms. Victor is a proponent of accessible, easy-to-use diagnostics and breakthrough solutions for advancing human health.
Tajinder Vohra - Senior Vice President, Global Operations
Tajinder Vohra is the Senior Vice President of Global Operations at Revvity. He oversees the company's manufacturing, supply chain, customer care, and distribution functions. With nearly 30 years of experience in operations management, Mr. Vohra leads a global team that works closely with R&D and Product Management to launch and manufacture products across Revvity's Life Sciences and Diagnostics businesses.
AI Analysis | Feedback
The key risks to Revvity's business include:
-
Intense Competition: Revvity operates in highly competitive life sciences and diagnostics sectors, facing numerous large and specialized players such as Thermo Fisher Scientific, Agilent Technologies, Danaher, Siemens Healthineers, Roche, and Abbott Laboratories. This dynamic environment necessitates continuous innovation to maintain market share against well-capitalized rivals, and ongoing consolidation among competitors could further threaten Revvity's market position.
-
Regulatory and Geopolitical Headwinds, Particularly in China: Revvity is significantly exposed to evolving regulatory landscapes and geopolitical factors. Specifically, changes in China's regulatory policies, such as DRG (Diagnosis-Related Group) reimbursement reforms that favor cheaper single-marker diagnostic tests over multiplex panels, have led to double-digit declines in Revvity's immunodiagnostics business in the region. This makes China a "major drag" on its diagnostics segment, with persistent uncertainty around future healthcare policy changes. Broader macroeconomic pressures, including tariffs, trade barriers, and foreign exchange fluctuations, also impact profit margins and disrupt supply chains globally.
-
Technological Disruption and the Imperative for Continuous Innovation: The rapid pace of technological advancement in the life sciences and diagnostics industries poses a significant risk. Revvity must continuously introduce new products and solutions to avoid technological obsolescence and prevent the loss of market share to competitors. Failure to keep pace with these changes and invest in timely innovation could adversely affect its competitive standing.
AI Analysis | Feedback
nullAI Analysis | Feedback
Revvity, Inc. operates in various addressable markets across its two segments: Discovery & Analytical Solutions and Diagnostics.Discovery & Analytical Solutions Segment
- Life Sciences Market (products, services, research): The global life science market size is projected to grow from USD 100.88 billion in 2025 to approximately USD 278.40 billion by 2034. The global life science research services market, a component of this, is calculated at USD 35.37 billion in 2025 and is predicted to increase to approximately USD 96.26 billion by 2035.
- Contract Research Organization (CRO) Services: The global contract research organization (CRO) services market size was valued at USD 92.27 billion in 2025 and is projected to reach USD 199.28 billion by 2034.
- Analytical Instrumentation Market: The global analytical instrumentation market size was valued at USD 41.8 billion in 2025 and is expected to grow to USD 71.9 billion in 2035. Another estimate places the global analytical instrumentation market size at USD 58.67 billion in 2025, projected to reach around USD 102.7 billion by 2035.
- Process Analytical Technology Market: The global process analytical technology market size is calculated at USD 4.00 billion in 2025 and is projected to surpass approximately USD 11.01 billion by 2035.
Diagnostics Segment
- Diagnostic Testing Market: The global diagnostic testing market size was calculated at USD 207.96 billion in 2025 and is predicted to surpass around USD 281.56 billion by 2035.
- Genetic Testing Market: The global genetic testing market size was valued at USD 37.32 billion in 2025 and is projected to grow to USD 93.94 billion by 2034. A more specific segment, the global genetic disease testing market, was valued at USD 937 million in 2024 and is projected to grow to USD 1.97 billion by 2032.
- Genomics Market (including genomic workflows for diagnostics): The global genomics market is estimated to be valued at USD 50.1 billion in 2025 and is projected to reach USD 304.8 billion by 2035.
- Clinical Laboratory Services Market: The global clinical laboratory services market size was valued at USD 291.01 billion in 2025 and is projected to grow to USD 545.79 billion by 2034.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Revvity (RVTY) over the next 2-3 years:
- New Product Launches and Software Innovations: Revvity anticipates a significant new product introduction cycle, particularly within its Signals business. Launches such as Synthetica, BioDesign, and Labgistics are expected to boost growth, with the Signals business projected to double in five years. Additionally, the Phenologic.AI™ software, introduced in January 2025, is designed to enhance cellular imaging workflows. In the Diagnostics segment, the company launched the IDS i20 ChLIA diagnostic analyzer and received U.S. regulatory approval for the T-SPOT TB test automation in Q2 2025.
- Growth in Diagnostics Segment (Immunodiagnostics and Reproductive Health): The Diagnostics segment is a key growth area, with the company seeing strong performance in both immunodiagnostics and reproductive health. Reproductive health and newborn screening are exhibiting "outsized growth," driven by geographic expansion and the detection of new disorders. Revvity aims to significantly increase its market penetration in U.S. immunodiagnostics, with a goal to double its revenue share from 20% to 40%.
- Stabilization and Improvement in Pharma Biotech Market: Revvity expects continued stabilization and growth in the broader pharma biotech market, along with anticipated improvements in pharmaceutical spending. The Life Science Solutions segment has shown differentiated performance, with expectations for improved platform sales, and sales into the pharma biotech sector saw low single-digit growth in Q4 2025 and for the full year.
- Strategic Re-segmentation and Operational Efficiency: The company is undertaking a strategic re-segmentation, effective fiscal year 2025, by integrating most of its Applied Genomics business into a new Life Sciences Solutions business. This restructuring is intended to streamline operations, create synergies, and sharpen customer focus, which is expected to position Revvity for sustained success across its key markets. Furthermore, Revvity is implementing its operating model to enhance operational efficiency and execution.
- Favorable Pricing Impact: Revvity anticipates a consistent positive impact from pricing, expecting at least 100 basis points of favorable price annually in the coming years.
AI Analysis | Feedback
Share Repurchases
- Revvity, Inc. authorized a new $1 billion share repurchase program in November 2024, replacing a previous program announced in May 2023.
- Over two and a half years leading up to March 2026, the company repurchased 15 million shares, representing 12% of its outstanding shares.
- Between March 31, 2025, and June 29, 2025, Revvity repurchased 3,102,232 shares for $292.66 million, contributing to a total of $586.86 million under the November 2024 buyback program.
Share Issuance
- The number of outstanding shares increased by 12.62% in 2021.
- Shares outstanding decreased by 2.28% in 2023, 2.25% in 2024, and 6.03% in 2025.
Outbound Investments
- In 2025, Revvity announced its acquisition of ACD/Labs, a provider of scientific software solutions, to enhance its Signals Software capabilities in analytical characterization and molecular design.
- In March 2025, Revvity acquired Project Farma, which offers consulting, quality, regulatory, and marketing services to the biopharma sector.
- In 2021, Revvity (then PerkinElmer) acquired BioLegend, Inc. for $5.7 billion to strengthen its Life Sciences segments, and also acquired Nexcelom and Oxford Immunotec in the same year.
Capital Expenditures
- Capital expenditures were -$73.52 million in the trailing 12 months (as of a recent report, likely late 2025/early 2026).
- For the full year 2025, capital expenditures totaled -$53.351 million, with -$18.501 million in Q4 2025.
- Capital expenditures for the full year 2024 were -$62.194 million.
Latest Trefis Analyses
Trade Ideas
Select ideas related to RVTY.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 03132026 | RVTY | Revvity | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 2.4% | 2.4% | -2.0% |
| 09122025 | RVTY | Revvity | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.4% | 5.9% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 152.56 |
| Mkt Cap | 26.1 |
| Rev LTM | 5,704 |
| Op Inc LTM | 1,136 |
| FCF LTM | 962 |
| FCF 3Y Avg | 980 |
| CFO LTM | 1,238 |
| CFO 3Y Avg | 1,241 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.8% |
| Rev Chg 3Y Avg | -1.0% |
| Rev Chg Q | 5.4% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 0.8% |
| Op Inc Chg 3Y Avg | -7.0% |
| Op Mgn LTM | 18.5% |
| Op Mgn 3Y Avg | 14.9% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 20.5% |
| CFO/Rev 3Y Avg | 18.7% |
| FCF/Rev LTM | 16.2% |
| FCF/Rev 3Y Avg | 15.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 26.1 |
| P/S | 4.2 |
| P/Op Inc | 25.1 |
| P/EBIT | 20.7 |
| P/E | 25.8 |
| P/CFO | 18.8 |
| Total Yield | 4.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.1% |
| 3M Rtn | -19.7% |
| 6M Rtn | -16.5% |
| 12M Rtn | 9.7% |
| 3Y Rtn | -22.5% |
| 1M Excs Rtn | -8.6% |
| 3M Excs Rtn | -23.3% |
| 6M Excs Rtn | -22.4% |
| 12M Excs Rtn | -23.2% |
| 3Y Excs Rtn | -100.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Life Sciences | 1,399 | 1,292 | 1,293 | 898 | 1,716 |
| Diagnostics | 1,356 | 1,458 | 2,020 | 2,933 | 2,067 |
| Revenue purchase accounting adjustments | -1 | -3 | |||
| Total | 2,755 | 2,751 | 3,312 | 3,828 | 3,783 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Life Sciences | 467 | 489 | 503 | 282 | 183 |
| Diagnostics | 354 | 320 | 782 | 1,433 | 874 |
| Purchase accounting adjustments | 0 | -5 | -46 | -41 | |
| Significant environmental matters | 0 | -2 | 0 | ||
| Transformation costs | 0 | ||||
| Significant litigation matters and settlements | -8 | -0 | 1 | ||
| Restructuring and other, net | -17 | -27 | -14 | -18 | |
| Asset impairment | -23 | 0 | 0 | ||
| Acquisition and divestiture-related costs | -25 | -69 | -40 | -63 | |
| Corporate expenses | -42 | -40 | -73 | -77 | -79 |
| Amortization of intangible assets | -359 | -365 | -371 | -257 | |
| Total | 347 | 301 | 743 | 1,258 | 979 |
Price Behavior
| Market Price | $86.77 | |
| Market Cap ($ Bil) | 9.8 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -26.3% | |
| 50 Days | 200 Days | |
| DMA Price | $91.39 | $94.55 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -5.1% | -8.2% |
| 3M | 1YR | |
| Volatility | 39.7% | 37.6% |
| Downside Capture | 1.50 | 1.05 |
| Upside Capture | 77.53 | 121.97 |
| Correlation (SPY) | 58.3% | 50.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.47 | 1.62 | 1.63 | 1.49 | 1.27 | 1.02 |
| Up Beta | 2.93 | 1.58 | 1.81 | 1.68 | 1.19 | 0.94 |
| Down Beta | 1.45 | 2.34 | 1.57 | 1.29 | 1.16 | 1.02 |
| Up Capture | 101% | 90% | 173% | 187% | 135% | 70% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 13 | 24 | 34 | 63 | 125 | 367 |
| Down Capture | 152% | 166% | 154% | 134% | 135% | 106% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 9 | 18 | 29 | 63 | 127 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | -7.1% | 37.6% | -0.12 | - |
| Sector ETF (XLV) | 7.7% | 15.8% | 0.28 | 55.9% |
| Equity (SPY) | 34.0% | 12.6% | 2.05 | 50.7% |
| Gold (GLD) | 42.9% | 27.2% | 1.29 | 0.8% |
| Commodities (DBC) | 46.4% | 18.0% | 1.97 | -12.6% |
| Real Estate (VNQ) | 14.2% | 13.3% | 0.74 | 43.7% |
| Bitcoin (BTCUSD) | -16.6% | 42.1% | -0.32 | 30.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | -7.9% | 33.5% | -0.18 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 57.1% |
| Equity (SPY) | 12.7% | 17.1% | 0.58 | 53.4% |
| Gold (GLD) | 21.2% | 17.8% | 0.97 | 10.5% |
| Commodities (DBC) | 14.5% | 19.1% | 0.62 | 5.7% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 49.8% |
| Bitcoin (BTCUSD) | 7.0% | 56.3% | 0.34 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | 6.0% | 30.4% | 0.25 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 59.3% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 57.7% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | 8.6% |
| Commodities (DBC) | 10.1% | 17.8% | 0.47 | 13.8% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 44.1% |
| Bitcoin (BTCUSD) | 68.3% | 66.9% | 1.07 | 14.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/2/2026 | -1.6% | -6.6% | -11.8% |
| 10/27/2025 | -1.7% | -5.4% | 1.7% |
| 7/28/2025 | -8.3% | -14.9% | -11.1% |
| 4/28/2025 | 0.8% | -0.3% | -2.2% |
| 1/31/2025 | -0.6% | -6.1% | -13.0% |
| 11/4/2024 | 3.1% | 1.2% | -5.0% |
| 7/29/2024 | 9.1% | 7.1% | 5.2% |
| 4/29/2024 | 3.5% | -0.9% | 10.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 7 | 11 |
| # Negative | 13 | 17 | 13 |
| Median Positive | 3.5% | 6.9% | 5.2% |
| Median Negative | -1.7% | -5.1% | -8.8% |
| Max Positive | 9.1% | 10.9% | 19.1% |
| Max Negative | -16.1% | -14.9% | -13.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/2/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 2.96 Bil | 2.98 Bil | 2.99 Bil | 4.2% | Higher New | Actual: 2.85 Bil for 2025 | |
| 2026 Organic Revenue Growth | 2.0% | 2.5% | 3.0% | -16.7% | -0.5% | Lower New | Actual: 3.0% for 2025 |
| 2026 Adjusted EPS | 5.35 | 5.4 | 5.45 | 9.1% | Higher New | Actual: 4.95 for 2025 | |
Prior: Q3 2025 Earnings Reported 10/27/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 2.83 Bil | 2.85 Bil | 2.88 Bil | -0.2% | Lowered | Guidance: 2.86 Bil for 2025 | |
| 2025 Organic Revenue Growth | 2.0% | 3.0% | 4.0% | 0 | 0 | Affirmed | Guidance: 3.0% for 2025 |
| 2025 Adjusted EPS | 4.9 | 4.95 | 5 | 1.0% | 5.0% | Raised | Guidance: 4.9 for 2025 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.